Qiming Venture Partners

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.

Zhang Ao

Executive Director

Cyrus Chan

Associate

Nan Chen

Principal

David Chu

Partner

Anna French

Managing Partner

Yuxin Fu

Vice President

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho

Venture Partner

William Hu

Managing Partner

Duane Kuang

Founding Managing Partner

Nisa Leung

Managing Partner

Dingzheng Li

Vice President

Jing Liu

Vice President

Chang Liu

Associate

Bin Liu

Vice President

Biao Lu

Associate

Shuo Mao

Principal

Gary Rieschel

Founder and Managing Partner

Motao Sun

Vice President

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Bonnie Wang

Principal

Rachel Wang

Venture Partner

James Wang

Venture Partner

Jing Wu

Partner

Gillian Xu

RMB funds CFO

Peter (Ming) Yin

Principal, Cleantech

Janet Yu

Partner

Yafeng Zhou

Associate

Alex Zhou

Partner

Zhiyuan Zhou

Associate

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Past deals in Series C

Singular Medical

Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.

Pulnovo Medical

Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Bioheng

Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

iMile

Series C in 2024
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Dezhen Technology

Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

Yidao Biotechnology

Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

DH-Robotics

Series C in 2024
DH-Robotics is a high-tech company that provides precision and motion control core components for industrial intelligent manufacturing scenarios. Their products include voice coil actuators, miniature electric table-type cylinders, electric grippers, and rotary electric grippers. They are confident that easy and adaptable intelligent identification and capture will provide robots with enhanced perception and execution capabilities.

Alamar Biosciences

Series C in 2024
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Leapstack

Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.

SinoUnited Health

Series C in 2023
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

Prismlab China

Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, electrical technology, and computer software and hardware, along with photopolymer materials, to produce advanced rapid prototyping machines based on SLA technology. With a global presence, its products are distributed across over 50 countries and regions, earning recognition and acclaim from users worldwide for their performance and innovation.

Fushoukang

Series C in 2022
Fushoukang is a home medical care services organization. They offer home medical care, nursing, and rehabilitation services. They provide long term services, institutional care, home care, smart home beds, and hospitcal escorts for the healthy self care elderly, semin disabled elderly , sick elderly, and demented elderly, and more services.

Tasogare

Series C in 2022
Tasogare Coffee is a premium coffee brand based in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, catering to a wide customer base that values high-quality coffee. Tasogare Coffee is committed to delivering exceptional coffee experiences, emphasizing quality in its offerings.

Belief Biomed

Series C in 2022
Belief Biomed brings the latest research achievements in precision medicine in Triangle area into production and promotes international collaboration by connecting established investors from China to explore the vast opportunity of North Carolina.

EigenCOMM

Series C in 2022
EigenCOMM Ltd. is a Shanghai-based company established in 2017, specializing in the research, development, and sales of cellular network internet chips. The firm focuses on providing complete solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. EigenCOMM's product line includes standard NB-IoT terminal chips, which ensure comprehensive coverage of cellular data connections and extended standby times, positioning the company as a key player in the IoT market.

Zhenge Biotech

Series C in 2022
Zhenge Biotech is a macromolecular pharmaceutical contract development and manufacturing organisation.

Yesmro

Series C in 2022
Yesmro, also known as Yimai Gongpin, is a retail company focused on supplying automation parts and industrial supplies to small and medium-sized enterprises. The company offers an extensive range of products, including electrical accessories, wires and cables, and industrial control components, catering specifically to the needs of businesses involved in technological development. By leveraging technology and data-driven approaches, Yesmro aims to deliver affordable and convenient solutions, enabling small enterprises to easily access the industrial products they require for their operations. The company's commitment to providing long-tail services ensures that even niche market needs are met efficiently and cost-effectively.

Abogen Biosciences

Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

WeRide

Series C in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.

Insilico Medicine

Series C in 2021
Insilico Medicine, Inc. is a biotechnology company that utilizes artificial intelligence to advance drug discovery, biomarker development, and research into aging. Founded in 2014 and based in Baltimore, Maryland, the company has developed a comprehensive AI platform that employs techniques such as generative adversarial networks and reinforcement learning to create novel molecular structures aimed at treating cancer and age-related diseases. Insilico Medicine operates various projects, including Pharma.AI, which offers machine learning services to biotechnology and pharmaceutical companies, and Young.AI, which predicts biological age. The company is actively engaged in internal drug discovery efforts targeting conditions like Alzheimer's disease, Parkinson's disease, and diabetes, and has partnered with Life Extension to produce nutraceutical products using advanced bioinformatics. Additionally, Insilico Medicine provides consumer applications and services to academic institutions and the cosmetic industry, solidifying its role in the intersection of AI and healthcare.

BrainHealth

Series C in 2021
BrainHealth focuses on the research and development, production, and sales of neurological medical equipment.

Yidao Biotechnology

Series C in 2021
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

P&R Measurement Technology

Series C in 2021
P&R Measurement Technology Co., Ltd., founded in 2011 and headquartered in Zhuhai, China, specializes in the research, development, and supply of testing and automation solutions. The company caters to various industries, including motors, household appliances, consumer electronics, and energy power. With a strong emphasis on engineering signal processing and acoustic/vibration testing, P&R Measurement offers a range of custom and semi-custom engineering testing equipment, as well as data processing and finite element simulation analysis services. The company operates subsidiaries in Guangzhou, Suzhou, Hong Kong, and the United States, with additional offices in Qingdao, Hefei, Shunde, and Ningde, enhancing its capacity to serve a diverse clientele.

SinoUnited Health

Series C in 2021
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

CastBox

Series C in 2021
CastBox is a spoken audio platform founded in 2016 and based in Beijing, China, with additional offices in Hong Kong and San Francisco. The platform allows users to easily find, access, and enjoy a wide range of spoken audio content, including podcasts, on-demand radio, and audiobooks, across multiple devices such as mobile phones, desktops, and smart home devices. CastBox employs proprietary technology, including curated podcast recommendations and an in-audio deep search feature powered by natural language processing and machine learning. This technology enables the platform to deliver personalized listening experiences tailored to individual user preferences and habits. The service is available in multiple languages, making it accessible to a global audience.

Matrixport

Series C in 2021
Matrixport is a comprehensive financial services platform focused on digital assets, allowing users to invest, trade, and leverage cryptocurrencies. It offers a blockchain-based platform that facilitates trading, custody, lending, and asset management of crypto assets. By providing these services, Matrixport enables users and clients to effectively manage their finances and capital in the evolving digital currency landscape.

Booming Technologies

Series C in 2021
Booming Tech is a cloud-based game and virtual reality platform that enables creators to innovate.

Fucunbao

Series C in 2021
Fucunbao is an application that provides medical management solutions specifically designed for rural communities in China. It operates an online insurance and medical portal that enables users to pay for insurance online, create reimbursement plans, and identify disease types. The platform aims to enhance access to insurance and medical services for underserved populations. By leveraging government funding and resources, Fucunbao helps subsidize insurance and medical expenses, addressing the financial burdens that often result from healthcare challenges in these areas.

Newsoara

Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Liangyihui

Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.

Yunji Technology

Series C in 2021
Yunji Technology is a Chinese company that specializes in the development of commercial service robots designed to improve efficiency and reduce costs in customer service operations. Its robots are aimed at enhancing service experiences across various sectors, including hospitality, luxury retail, and restaurants. By automating certain aspects of customer service, Yunji Technology's solutions enable clients to save time and streamline their operations, ultimately empowering businesses to deliver improved services to their customers.

Insight Lifetech

Series C in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

dMed

Series C in 2020
dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Nice Tuan

Series C in 2020
Nice Tuan is an e-commerce platform that specializes in providing fresh produce, beverages, leisure food, and daily supplies. The company operates a community-focused model, partnering with local residential communities to source products from nearby warehouses and producers. This approach allows Nice Tuan to offer a wide range of daily groceries and household items to residents, aiming to create an efficient and convenient shopping experience. By emphasizing local sourcing and community engagement, Nice Tuan seeks to establish a robust e-commerce ecosystem tailored to the needs of its customers.

ZEGOCLOUD

Venture Round in 2020
Our journey in audio and video hardware and software development started back in 2001. The core team focused on key technologies in digital signals, algorithms for voice and video, as well as network transmission. We’ve learned from years of experience that delivering real-time audio and video is no easy feat. It can only be achieved with a wealth of knowledge in many different fields. Yet in this digital era, there are so many use cases for voice and video interaction to build bridges and forge links. So we started to explore how to share our passion for and expertise in audio and video solutions with more businesses and developers as a partner in their journey of success. That’s why we founded ZEGOCLOUD in 2015. With Real-Time Communication (RTC) empowered by AI, ZEGOCLOUD now seeks to turn the vision for Real-Time Interaction (RTI) into a reality. We lay the groundwork for businesses and developers to build RTI into their apps across mobile internet and the metaverse. Flexible, customizable, low code.

Broncus Medical

Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, particularly emphysema. The company is known for its Exhale product line, which features the patented Airway Bypass technique, potentially being the first minimally-invasive procedure for homogeneous emphysema, a common form of the disease affecting many patients. Broncus is actively enrolling participants in its pivotal EASE Trial to evaluate this innovative treatment for severe homogeneous emphysema. In addition to its emphysema-focused efforts, Broncus operates within the interventional pulmonology sector, offering a range of products designed to enhance the diagnosis and treatment of lung conditions, including lung cancer and chronic obstructive pulmonary disease (COPD). The company is headquartered in Mountain View, California, with an international presence in Nyon, Switzerland.

Petkit

Series C in 2020
Petkit is a technology company that is focused on the development of smart products for pets. It offers an activity monitor that is able to record and analyze pets’ calorie consumption, health, and mood and track their location. Petkit was founded by Weixue Guo and Weike Guo in 2013.

Antengene

Series C in 2020
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.

LetsGetChecked

Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.

Yunyinggu

Series C in 2020
Yunyinggu is a Chinese company dedicated to developing and promoting new display technologies that can significantly improve the performance of flat panel displays. The company’s proprietary solution is the world’s best in achieving high PPI (pixel per inch) and can be applied to all kinds of flat panels such as LCD, LED, OLED and others.

DiNovA Medtech

Series C in 2020
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.

Shulan Health

Series C in 2020
Shulan Hospital is a hospital center that provides rehabilitation, nutrition, health examination, and remote-consultation services.

Abbisko Therapeutics

Series C in 2020
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Element Science

Series C in 2020
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.

IntoCare

Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Jacobio Pharmaceuticals

Series C in 2020
Jacobio Pharmaceuticals, established in 2015 in Beijing, is a clinical-stage biotech company focused on developing innovative drugs to address unmet medical needs in China and internationally. The company aims to become a global leader in providing transformative therapies for serious conditions, including cancer, autoimmune, and infectious diseases. Founded by experienced executives from prominent pharmaceutical companies, Jacobio has quickly built a robust drug research and development team exceeding 100 employees, equipped with comprehensive capabilities covering target discovery, medicinal chemistry, pharmacology, and clinical development. The company boasts a promising pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced. This program targets a novel potential for both immunotherapy and targeted therapy and is currently undergoing Phase I clinical trials in the United States, with approvals secured for trials in China.

DST Car

Series C in 2020
Dishangtie is a Shenzhen-based new energy vehicle rental service platform targeting the transportation and logistics industry.

KeChow Pharma

Series C in 2019
KeChow Pharma, Inc. is a biopharmaceutical company focused on novel drug discovery.

SinoUnited Health

Series C in 2019
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.

DiNovA Medtech

Series C in 2019
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.

NEIWAI

Series C in 2019
Founded in 2012, NEIWAI’s mission is to make solutionwear for modern women. We specialize in making comfortable underwear, loungewear, and athleisure with an emphasis on technology and innovation. More than just stylish and comfortable, our clothing is Made to Live in. NEIWAI is about feeling good inside and outside. We encourage and support what we call the Inhale-Exhale Lifestyle, by listening to the rhythms of your body. Our clothes with our blends of fabric provide proper fit and support physically and emotionally throughout your day and throughout your life. We also encourage Buy Less, Buy Better - a more sustainable consumer environment by focusing on quality over quantity.

Yunyinggu

Series C in 2019
Yunyinggu is a Chinese company dedicated to developing and promoting new display technologies that can significantly improve the performance of flat panel displays. The company’s proprietary solution is the world’s best in achieving high PPI (pixel per inch) and can be applied to all kinds of flat panels such as LCD, LED, OLED and others.

Amphivena Therapeutics

Series C in 2019
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.

Tisenc

Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.

Hesai Technology

Series C in 2019
Hesai Technology, founded in 2014 and headquartered in Shanghai, China, specializes in the development, manufacture, and sale of three-dimensional light detection and ranging solutions, commonly known as LiDAR. The company focuses on designing advanced laser radar systems that support a variety of applications, primarily in autonomous and semi-autonomous vehicles equipped with advanced driver assistance systems. Additionally, Hesai's technology is utilized in other sectors, such as robotics for last-mile delivery and industrial processes, as well as in natural gas leak detection systems. The organization has structured its operations into two main segments: LiDAR and gas detection, with the LiDAR segment generating the majority of its revenue.

Huimei Technology

Series C in 2019
Huimei Technology specializes in developing medical artificial intelligence solutions aimed at enhancing clinical quality and patient outcomes. The company offers a range of core products, including a single disease process quality management system and a Clinical Decision Support System (CDSS), which integrates an evidence-based medical knowledge base. Utilizing advanced technologies such as natural language processing and deep learning, Huimei Technology processes clinical big data to provide real-time assistance to healthcare professionals during critical decision-making moments. Their solutions are designed to streamline workflows by integrating standard electronic clinical paths, thereby helping clinicians make more personalized and effective diagnosis and treatment decisions based on individual patient conditions. The company's products are primarily targeted at large hospitals, with applications in outpatient, emergency, and ward settings.

Webuy Group

Series C in 2019
Founded in 2017, Webuy/Jingling Group is a social e-commerce company which owns brands including Shaking Baby (甩甩宝宝), Haoyiku (好衣库) and 芝麻云仓. Webuy Group is a community-based e-commerce platform. It enables merchants to share links to sale items in the app to WeChat, China's most popular social media app, where shoppers can directly make their purchases.

Haoyiku

Series C in 2019
Haoyiku is a community-based e-commerce platform founded in 2017 by Qiangqiang Wu and based in Hangzhou. The company focuses on apparel and employs a unique S2b2C model, connecting suppliers, businesses, and consumers. By leveraging social networks and the WeChat app, Haoyiku facilitates a seamless shopping experience that includes rapid payment settlements and enhanced customer outreach. This model not only allows partner brands to efficiently off-load inventory but also enables individual merchants to sell products within their social circles, contributing to a low return rate and ongoing business improvement through training and support.

RedDoorz

Series C in 2019
RedDoorz is an online platform that facilitates the discovery and booking of budget accommodations across Southeast Asia. Founded in 2015 and headquartered in Singapore, the platform connects travelers with a network of standardized budget hotels and guesthouses, primarily offering two-star and three-star properties. RedDoorz provides hotel partners with tools to enhance their visibility, manage distribution, marketing, customer experience, and pricing, thereby improving their operational efficiency and revenue potential. The company employs over 1,000 people across five countries and has received backing from notable investors, including Jungle Ventures and the International Finance Corporation. With a focus on delivering reliable stays, RedDoorz ensures that travelers benefit from essential amenities such as free Wi-Fi, clean rooms, and comfortable beds.

Delta Medical

Series C in 2019
Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.

WorkTrans

Series C in 2019
WorkTrans is a human resource management software developer based in China that offers a comprehensive platform designed to enhance various HR functions. The company's software provides diversified attendance management, mobile scheduling, and unified oversight, facilitating efficient payroll processing, roster management, recruitment, and training. By streamlining these processes, WorkTrans aims to improve recruiting efficiency and expand development opportunities for its clients, allowing organizations to adapt to their evolving workforce needs.

New Horizon Health

Series C in 2019
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.

Hesai Technology

Series C in 2019
Hesai Technology, founded in 2014 and headquartered in Shanghai, China, specializes in the development, manufacture, and sale of three-dimensional light detection and ranging solutions, commonly known as LiDAR. The company focuses on designing advanced laser radar systems that support a variety of applications, primarily in autonomous and semi-autonomous vehicles equipped with advanced driver assistance systems. Additionally, Hesai's technology is utilized in other sectors, such as robotics for last-mile delivery and industrial processes, as well as in natural gas leak detection systems. The organization has structured its operations into two main segments: LiDAR and gas detection, with the LiDAR segment generating the majority of its revenue.

zuzuche.com

Series C in 2019
ZuzuChe.com operates an online platform that facilitates car rental services both in China and internationally. Founded in 2011 and headquartered in Guangzhou, the company provides users with access to comprehensive car rental information, enabling searches for designated driving, car chartering, and special events across more than 200 cities in China. ZuzuChe offers a wide range of services, including overseas car rentals, local attractions, Chinese GPS, and international driver's license translation. Additionally, the platform provides various insurance options, such as car damage theft insurance and personal liability coverage. Users can also book tickets and hotels through the platform, which is accessible via a mobile application. By integrating advanced search technology and real-time pricing comparisons, ZuzuChe aims to create a convenient and user-friendly experience for travelers.

Insta360

Series C in 2019
Insta360 is a professional intelligent technology company that offers cameras that empowers people to freely share experiences. The company makes cameras that allow you to share everything, everywhere. From the 8K Insta360 Pro for professional creators, to the matchlessly versatile Insta360 ONE, Insta360's cameras allows to capture big moments in immersive detail. Founded in 2014, Insta360 is the world leader in 360-degree cameras. Based in Shenzhen and immersed in the city’s incomparable hardware ecosystem, Insta360 prides itself on creating groundbreaking products that push the envelope of both performance and accessibility. With an Insta360 camera, users can take 360-degree photos and videos in high definition, and live-stream their experiences directly onto Facebook, Twitter, YouTube and other social platforms. When viewed in a VR headset, Insta360 experiences can transport people into places and moments they’ve never before imagined.

Zuiyou

Series C in 2019
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content such as recommendations, topics, and videos. The platform emphasizes a unique approach to user engagement by decentralizing comments, presenting them in an order that does not prioritize popularity. This innovative method encourages a more diverse range of interactions and allows users to connect over shared interests in a way that differs from traditional social media structures.

Petkit

Series C in 2019
Petkit is a technology company that is focused on the development of smart products for pets. It offers an activity monitor that is able to record and analyze pets’ calorie consumption, health, and mood and track their location. Petkit was founded by Weixue Guo and Weike Guo in 2013.

Microtech Medical

Series C in 2018
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

APT Medical

Series C in 2018
APT Meidcal Inc.Founded in October 2006, Shenzhen APT Medical Devices Co., Ltd. is a high-tech enterprise integrating the development, production and sale of minimally invasive cardiovascular interventional devices. The company has production bases at Guanlan in Shenzhen and Xiangxiang in Hunan.

Akulaku

Series C in 2018
Akulaku Inc., founded in 2016 and based in Jakarta, Indonesia, is a prominent banking and digital finance platform in Southeast Asia, operating in countries such as Indonesia, the Philippines, and Malaysia. The company focuses on addressing the financial needs of underserved customers in emerging markets by providing a variety of services, including digital banking, financing, investment, and insurance brokerage. Akulaku offers a virtual credit card and an e-commerce platform, along with Asetku, an online wealth management service, and a mobile digital bank known as Neobank, which is supported by Bank Neo Commerce. The company aims to enhance users' shopping experiences by facilitating installment purchases and providing a wide range of virtual payment services, such as mobile top-ups and bill payments. Akulaku's mission is to serve 50 million users across Southeast Asia by 2025.

ET Healthcare

Series C in 2018
ET Healthcare, Inc. is an in vitro diagnostics company that specializes in manufacturing central laboratory analyzers for both inpatient and outpatient testing in various hospital settings, including pediatric care, intensive care units, and emergency rooms. The company has developed the Pylon Immunochemistry System, which integrates laboratory analysis with point-of-care testing to meet diverse immunodiagnostic needs, such as inflammation, cardiac function, fertility, infectious diseases, and tumor detection. Additionally, the Pylon BNP Immunoassay supports heart failure management by measuring B-type natriuretic peptide levels in plasma. ET Healthcare's products aim to bring the performance of traditional central lab analyzers to near-patient settings, addressing requirements for space, plumbing, and staffing. Headquartered in Palo Alto, California, the company also has offices in Shanghai and manufacturing facilities in Suzhou, China.

SequoiaDB

Series C in 2018
SequoiaDB Corporation is a distributed database company based in Shenzhen, China, established in 2011. It offers a range of products, including SequoiaDB, an enterprise-class distributed relational database designed for online transactions, data centers, and content management applications, as well as SequoiaCM, a solution for managing unstructured data in large and medium-sized enterprises. The company provides services in online transaction processing, content management, and data lake solutions, primarily catering to financial institutions such as banks, insurance firms, and securities companies. SequoiaDB is committed to research and development, aiming to become a global leader in the database industry, and has been recognized in Gartner's reports for its innovative database systems.

Jacobio Pharmaceuticals

Series C in 2018
Jacobio Pharmaceuticals, established in 2015 in Beijing, is a clinical-stage biotech company focused on developing innovative drugs to address unmet medical needs in China and internationally. The company aims to become a global leader in providing transformative therapies for serious conditions, including cancer, autoimmune, and infectious diseases. Founded by experienced executives from prominent pharmaceutical companies, Jacobio has quickly built a robust drug research and development team exceeding 100 employees, equipped with comprehensive capabilities covering target discovery, medicinal chemistry, pharmacology, and clinical development. The company boasts a promising pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced. This program targets a novel potential for both immunotherapy and targeted therapy and is currently undergoing Phase I clinical trials in the United States, with approvals secured for trials in China.

CANbridge Pharmaceuticals

Series C in 2018
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Zuiyou

Series C in 2018
Zuiyou is a social networking mobile application designed for users born in the 1990s, facilitating the sharing and discovery of content such as recommendations, topics, and videos. The platform emphasizes a unique approach to user engagement by decentralizing comments, presenting them in an order that does not prioritize popularity. This innovative method encourages a more diverse range of interactions and allows users to connect over shared interests in a way that differs from traditional social media structures.

Moretickets

Series C in 2018
Moretickets is an online ticketing company based In Shanghai.

Lanjinrong

Series C in 2018
Lanjinrong is a Beijing Based Fintech Start Up.

Bang Er Orthopedic

Series C in 2018
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

Eceyes Internet Financial

Series C in 2018
Eceyes Internet Financial is an insurance technology platform offering insurance and related products.

Miaoshou Doctor

Series C in 2018
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Bondent

Series C in 2018
Bondent is a provider of integrated oral medical solutions tailored for the oral health and dental industry. The company specializes in the design, development, manufacturing, and sales of oral medical equipment, creating a comprehensive ecosystem that supports dental practices. In addition to its product offerings, Bondent provides technical training and management consulting services to enhance the operational capabilities of its clients. This approach ensures that dental professionals have access to both the tools and the knowledge necessary to deliver high-quality oral health care.

Xiaoman Technology

Series C in 2018
Xiaoman Technology, established in 2013 and based in Shenzhen, China, specializes in providing foreign trade solutions that leverage big data and artificial intelligence. The company develops SaaS-based business management services that encompass customer relationship management, marketing, sales management, and other core business functions. Its offerings are designed to be flexible and compatible, catering to the standardization needs of small and micro enterprises while also addressing the customization requirements of larger organizations. By focusing on comprehensive customer-oriented research and development, as well as effective sales, marketing, and service strategies, Xiaoman Technology aims to enhance customer service, improve sales productivity, and help businesses expand their international operations.

Tiebaobei

Series C in 2017
Armored two mobile phone is Beijing Cinda Public Alliance Technology under the domestic leader in second-hand construction machinery service platform, is committed to creating a new c2c second-hand equipment trading model, using the Internet to solve the traditional thinking of second-hand construction machinery trade pain points for all buyers worldwide The most fair, most efficient and most friendly construction machinery service platform.

Bioscience

Series C in 2017
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.

Bang Er Orthopedic

Series C in 2017
Zhejiang Boner Medical Investment Management Co., Ltd. is a well-known professional hospital investment operator in the Yangtze River Delta, featuring major orthopaedics and rehabilitation.

Venus Medtech

Series C in 2017
Venus MedTech (Hangzhou) Inc. specializes in the development and commercialization of transcatheter heart valve medical devices, primarily serving Mainland China and international markets. The company's flagship products include the VenusA-Valve, designed for the treatment of severe aortic stenosis, and the upgraded VenusA-Plus. Additionally, Venus MedTech offers the VenusP-Valve for right ventricular outflow tract dysfunction, along with balloon aortic valvuloplasty catheter systems and the TriGUARD3 cerebral embolic protection device, which aims to reduce the risk of cerebral damage during structural heart procedures. Founded in 2009 and headquartered in Hangzhou, the company is positioned to meet the growing clinical demands for interventional artificial cardiac valve solutions, having already completed clinical tests for its products in China.

Hypereal

Series C in 2017
Hypereal is a virtual reality technology company based in Minhang, China, specializing in the manufacturing and marketing of electronic equipment for immersive virtual reality experiences. The company offers a range of products, including the HyPano head-mounted display, HyFeels hand controllers, and supporting devices like HyBeacons and the Hybox, which serves as a link center. Hypereal is unique in China for having its own comprehensive software ecosystem, which includes VR headsets, a positioning tracking system, interactive controllers, an SDK, and an in-house game development team. By providing a complete VR solution that encompasses hardware, software, and content operations, Hypereal enables users to experience a fully immersive 360-degree virtual environment.

ARMO BioSciences

Series C in 2017
ARMO BioSciences, Inc. is an immuno-oncology company based in Redwood City, California, focused on developing biologic therapeutics that stimulate the immune system to combat cancer. The company's product pipeline includes several innovative candidates, such as AM0010, a long-acting form of interleukin-10 that enhances immune response, and AM0001, an anti-PD-1 monoclonal antibody targeting various cancers. Other key products in development include an anti-LAG-3 checkpoint inhibitor, AM0015, a recombinant form of interleukin-15, and AM0012, a recombinant interleukin-12. Established in 2010 and formerly known as Targenics, ARMO BioSciences aims to activate and enhance the body's immune response against tumors, thereby improving outcomes for cancer patients. As of mid-2018, it operates as a subsidiary of Eli Lilly and Company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.